FDA Rejects Merck's Latest COX-2 Drug
Merck received a “non-approvable letter” from the FDA on Friday in response to its New Drug Application for Arcoxia. The FDA said Merck would have to provide additional data on Arcoxia to garner regulatory approval.
“We’re evaluating the letter,” said Merck spokesman Ron Rogers on Monday....
To view the full article, register now.